(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide;hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide;hydrochloride
• 化学式: C19H27ClN4O9
• 分子量: 490.9
• InChiKey: XAMOGPAEMYKWBG-MPDITTGVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.28
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  252
• 氢给体数：
  12
• 氢受体数：
  12

文献信息

• Pharmaceutical composition, excipient for the composition and use of the composition
  申请人：Prati, Donaduzzi & Cia Ltda

  公开号：US11389423B2

  公开（公告）日：2022-07-19

  A pharmaceutical composition containing synthetic Cannabidiol and its use in obtaining a medication for the treatment of neurological disorders, as well as the main excipients used in the production process, in addition to its small, medium, and large-scale preparation process. The use of the composition for the treatment of neurological disorders in human or animal populations, in particular in the treatment of Parkinson's disease, in the range of 300 to 850 mg/day or at daily doses of 100 to 1750 mg for neuroprotective action.

  一种含有合成大麻二酚的药物组合物及其在获得治疗神经系统疾病药物中的用途，以及生产过程中使用的主要辅料，此外还有其小型、中型和大型制备工艺。该组合物用于治疗人类或动物的神经系统疾病，特别是帕金森病的治疗，剂量范围为 300 至 850 毫克/天，或每日剂量为 100 至 1750 毫克，具有神经保护作用。
• PHARMACEUTICAL COMPOSITION, EXCIPIENT FOR THE COMPOSITION AND USE OF THE COMPOSITION
  申请人：Prati, Donaduzzi & Cia Ltda

  公开号：US20200368197A1

  公开（公告）日：2020-11-26

  A pharmaceutical composition containing synthetic Cannabidiol and its use in obtaining a medication for the treatment of neurological disorders, as well as the main excipients used in the production process, in addition to its small, medium, and large-scale preparation process. The use of the composition for the treatment of neurological disorders in human or animal populations, in particular in the treatment of Parkinson's disease, in the range of 300 to 850 mg/day or at daily doses of 100 to 1750 mg for neuroprotective action.
• [EN] USE OF FAAH INHIBITORS AS NEUROPROTECTIVE AGENTS IN THE CNS<br/>[FR] UTILISATION DES INHIBITEURS DE FAAH COMME AGENTS NEUROPROTECTEURS DU SNC
  申请人：IRONWOOD PHARMACEUTICALS INC

  公开号：WO2014004676A1

  公开（公告）日：2014-01-03

  The present disclosure relates to methods of using a fatty acid amide hydrolase (FAAH) inhibitor of Formula I alone or in combination with one or more additional therapeutic agents for the treatment or prevention of neuronal injury or neurodegeneration in a patient in need thereof.